Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (NCT05832229)
Liver Cirrhosis Network (LCN) Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study
🩺 Plain-English Summary (8th-Grade Level)
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego NAFLD Research Center — La Jolla, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of California San Diego NAFLD Research Center — La Jolla, California
- Keck Medical Center of USC — Los Angeles, California
- LAC + USC Medical Center — Los Angeles, California
- UCSF/Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
- UCSF Medical Center — San Francisco, California
- University of Miami Health System — Miami, Florida
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- New York Presbyterian/Weill Cornell — New York, New York
- Columbia University Iriving School of Medicine — New York, New York
- Duke Liver Center — Durham, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Virginia Commonwealth University — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (312) 503-5536
Email: lcn@northwestern.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cirrhosis
- Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement — Richmond, Virginia
- Liver Cirrhosis Network Cohort Study — La Jolla, California
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis — Los Angeles, California
- Oral Health In Cirrhosis of the Liver (ORACLE) — Richmond, Virginia
- Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis — Ann Arbor, Michigan
- Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis — San Francisco, California
Explore by condition: All Cirrhosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.